1. Clinical & Scientific Overview
Diclofenac (Diclofenac Sodium & Diclofenac Potassium) (TIP-MED-000104, Reference Code [7.2]) is classified under
Pain, Inflammation, Rheumatology & Gout Medicines (Ch 07) as a Non-Steroidal Anti-Inflammatory Drug (NSAID); Non-Selective COX-1 and COX-2 Inhibitor (Relatively Higher COX-2 Selectivity).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug • Veterinary Use Banned in India (Drugs Rules Rule 105B).
Brufen (Abbott), Ibugesic (Cipla)
Enteric-Coated (Diclofenac Sodium) & Immediate-Release (Diclofenac Potassium) Tablets: 50 mg; Sustained-Release (SR) Tablets: 75 mg, 100 mg; IM/IV Injection: 75 mg/3 mL or 75 mg/1 mL (AQ); Suppository: 50 mg, 100 mg; Topical Gel: 1% w/w
3. Mechanism of Action & Pharmacodynamics
Reversibly inhibits cyclooxygenase isoenzymes COX-1 and COX-2 (with ~4- to 10-fold relative preference for COX-2), blocking conversion of arachidonic acid to pro-inflammatory prostaglandins (PGE2, PGI2) in peripheral tissues and synovial fluid. Accumulates in synovial fluid for 12+ hours despite a short 1–2 hour plasma half-life.
4. Therapeutic Indications & Evidence-Supported Uses
- Acute musculoskeletal pain, postoperative pain, dysmenorrhoea, and acute gouty arthritis
- Rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis
- Acute renal colic (ureteric spasm relief via PGE2 inhibition)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Adults: 50 mg orally 2–3 times daily (or 75–100 mg SR once daily; max 150 mg/day) for the shortest duration necessary. Topical Gel (1% w/w): apply 2–4 g 3–4 times daily.
Administration & Meal Timing: Oral (take after meals), Topical, or Deep Intramuscular / IV infusion.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Monitor transaminases; contraindicated in severe hepatic impairment.
Contraindicated in eGFR < 30 mL/min; inhibits vasodilatory renal prostaglandins (PGE2/PGI2) and constricts the afferent arteriole, precipitating acute kidney injury.
Monitor transaminases; contraindicated in severe hepatic impairment.
7. Contraindications, Precautions & High-Risk Warnings
- Active peptic ulceration or gastrointestinal bleeding
- Established ischaemic heart disease, peripheral arterial disease, cerebrovascular disease, or congestive heart failure (NYHA II–IV) — high COX-2 prothrombotic CV risk
- NSAID/Aspirin-exacerbated respiratory disease (AERD / Samter's triad)
- Third trimester of pregnancy (premature closure of foetal ductus arteriosus) and CKD (eGFR < 30 mL/min)
Key Clinical Precautions: Monitor transaminases; contraindicated in severe hepatic impairment.
8. Adverse Effects Profile
- Gastrointestinal erosion, peptic ulceration, and GI haemorrhage
- Cardiovascular thrombotic events (myocardial infarction, stroke) — Diclofenac carries a CV risk comparable to selective coxibs due to high COX-2 inhibition
- Afferent arteriolar vasoconstriction, sodium/water retention, hyperkalaemia, and papillary necrosis
- Hepatocellular transaminase elevation
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- ACE Inhibitors / ARBs (Telmisartan) + Diuretics (Furosemide): 'Triple Whammy' acute kidney injury (afferent constriction + efferent dilation + hypovolaemia)
- Antiplatelets (Aspirin, Clopidogrel), Anticoagulants (Warfarin, Apixaban), SSRIs, Corticosteroids: marked increase in upper GI ulceration and bleeding
- Lithium & Methotrexate: decreases renal clearance and precipitates severe toxicity
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Take immediately after food with a full glass of water, and use the lowest effective dose for the shortest possible number of days.
- Consider co-prescribing a Proton Pump Inhibitor (Pantoprazole) in patients aged >60 yr or on low-dose Aspirin.
- LEGAL NOTE: Human Diclofenac multi-dose vials are banned for veterinary use in India (single-dose 1 mL human ampoules only) because Diclofenac caused catastrophic renal failure and near-extinction of Indian Gyps vultures.
Storage, Stability & Dispensing Safeguards: Store below 30°C.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2026) • NLEM 2022 (MoHFW) • CDSCO Approved Prescribing Information
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [7.4] Ibuprofen — Non-Steroidal Anti-Inflammatory Drug (NSAID); Propionic Acid Deri
- [7.5] Naproxen (and Naproxen Sodium) — Non-Steroidal Anti-Inflammatory Drug (NSAID); Long-Acting Propion
- [7.6] Etoricoxib — Selective Cyclooxygenase-2 (COX-2) Inhibitor (Coxib NSAID)
- [7.7] Tramadol Hydrochloride — Weak Centrally Acting Mu-Opioid Receptor Agonist & Serotonin/Nore